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In Reply:
Travis et al.1 were first to describe
large cell neuroendocrine lung carci-
noma (LCNELC) in 1991. Because this
new diagnosis shared many histologic
features with small cell lung carcinoma
(SCLC), but was classified as a non-
small cell ling cancer (NSCLC), there
has subsequently been great confusion
regarding how patients with LCNELC
should be treated.
Because SEER-17 contains ap-
proximately 26% of US population, we
felt that it would allow us sufficient
numbers to thoroughly analyze this rare
tumor in comparison to other large
cell carcinomas (OLC) and SCLC.2
SEER-17 does represent the translation
of this difficult diagnosis of LCNELC
across a broad spectrum of pathologists
who were using the World Health Orga-
nization classification after the strict dif-
ferentiation between the neuroendocrine
subtypes was delineated,3 and so it is
likely to be more representative of the
diagnostic spectrum encompassed by
this entity in the United States. Conse-
quently, the results of our study may be
more widely predictive of outcomes as
compared with smaller studies per-
formed at single institutions.
The Italian investigators were
concerned that our article does not re-
port information regarding diagnostic
criteria nor does it contain information
in regards to molecular/biomarker anal-
yses and response to chemotherapy. Un-
fortunately, these data are lacking from
SEER-17. We agree that prospective
clinical data are needed to determine the
most effective therapeutic approach to
LCNELC.
We applaud the efforts of
Asamura et al.4 to carefully re-evaluate
the histologic diagnosis for their study.
However, their study determined that
LCNEC was much more similar to
SCLC than to atypical carcinoid and
typical carcinoid tumors. Because our
group remained puzzled regarding
whether LCNELC should be treated as a
NSCLC or SCLC, we felt that the real
question was whether LCNELC was
more similar to SCLC than OLC. Cor-
relating our findings to those of
Asamura et al.4 must take into account
important methodologic and population
(Western versus Japanese) differences
between the two studies. Unfortunately,
smoking history is not available in
SEER-17. However, we feel that their
populations with the diagnosis of
SCLC and LCNELC may have more
of a male predominance because, un-
like the United States, the rates of
smoking among Japanese men have
been traditionally much higher than
women.5 Despite the noted differ-
ences, we also found it interesting that
the 4-year survival rates in our series
of all patients undergoing resection
(41% LCNELC and 32% SCLC) were
similar to the 5-year survivals in the
investigation by Asamaura et al. (40%
LCNELC and 36% SCLC). Similarly,
when the analysis was limited to stage
I surgical patients, the 4-year survival
of LCNELC and SCLC (60% and
37%, respectively) were similar to
their reported 5-year survival (58%
and 42%, respectively). The inability
to detect statistically significant sur-
vival differences in the Japanese study
may have been due to a smaller num-
ber of patients undergoing surgical re-
section in their series (324 and 355
patients with LCNELC and SCLC in
our SEER-17 series versus 141 and
113 in the study by Asamura et al.,
respectively).
In summary, we feel that the clas-
sification of LCNELC should remain
classified as NSCLC until prospective
studies demonstrate otherwise.
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